ArticleOncology letters2020
miR-202 functions as a tumor suppressor in hepatocellular carcinoma by targeting HK2.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Reprogramming Metabolism and Immunity: Nanotechnology's Promise for Hepatocellular Carcinoma Precision Therapy.International journal of nanomedicine · 2026Review
- The regulation of LRPs by miRNAs in cancer: influencing cancer characteristics and responses to treatment.Cancer cell international · 2025Review
- miR-10b-5p promotes tumor growth by regulating cell metabolism in liver cancer via targeting SLC38A2.Cancer biology & therapy · 2024Article
- Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review).Molecular medicine reports · 2024Review
- Role of microRNAs in glycolysis in gynecological tumors (Review).International journal of oncology · 2023Review
- The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.International journal of cancer · 2022Review
- The microRNA-202 as a Diagnostic Biomarker and a Potential Tumor Suppressor.International journal of molecular sciences · 2022Review
- The Metabolism Reprogramming of microRNA Let-7-Mediated Glycolysis Contributes to Autophagy and Tumor Progression.International journal of molecular sciences · 2021Review
- Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.Molecular and cellular biochemistry · 2021Article
- Article
- NR2F1-AS1/miR-140/HK2 Axis Regulates Hypoxia-Induced Glycolysis and Migration in Hepatocellular Carcinoma.Cancer management and research · 2021Article
- Downregulated lncRNA GAS5 and Upregulated miR-21 Lead to Epithelial-Mesenchymal Transition and Lung Metastasis of Osteosarcomas.Frontiers in cell and developmental biology · 2021Article
- Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma.World journal of gastroenterology · 2020Review
- Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence has suggested that microRNAs (miRNAs) can participate in metabolic reprogramming. Additionally, aerobic glycolysis is associated with tumor progression in hepatocellular carcinoma (HCC). In the present study, miRNA (miR)-202 expression levels were found to be significantly lower in HCC tissues compared with the corresponding adjacent non-cancerous tissue samples using reverse transcription-quantitative PCR analysis in 56 patients with HCC. Lower miR-202 expression levels were identified to be associated with tumor size, vascular invasion, Tumor, Node and Metastasis stages and poor overall survival rates in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.